
DOL Finalizes PBM Transparency Rule with Implications for Employers, Independent Pharmacies
Key Takeaways
- The rule covers PBMs and affiliated brokers/consultants serving large, self-insured ERISA plans, while excluding fully insured plans and plans sponsored by drug supply chain entities and affiliates.
- Required reporting captures direct and indirect compensation, including rebates, spread pricing, pharmacy recoupments, price protection payments, formulary incentives, and PBM-affiliated pharmacy steering arrangements.
New PBM compensation disclosures and audit rights could help employers spot reimbursement practices that hurt independent pharmacies, if they act.
An employer can pay more for a prescription while the pharmacy dispensing it receives less. Understanding how much of the employer’s payment reaches the pharmacy, and what the pharmacy benefit manager (PBM) retains, is essential to evaluating prescription drug costs. Those amounts are not always apparent from the PBM’s administrative fee or rebate guarantee.1
The US Department of Labor’s (DOL) final PBM fee disclosure rule, published November 2, 2026, gives covered plan fiduciaries greater access to information about PBM compensation and the records needed to verify it.1,2 The rule could also indirectly benefit independent pharmacies by allowing employers to unveil practices that affect pharmacy reimbursement and patient access. The result will depend on whether employers leverage the disclosures to negotiate better terms, investigate discrepancies, and hold PBMs accountable.
READ MORE:
Which Plans Are Covered and When the Rule Applies
The rule applies to providers of PBM services and affiliated brokers and consultants serving large, self-insured group health plans subject to the Employee Retirement Income Security Act (ERISA).1,2 Generally, covered plans include self-insured plans with at least 100 participants or those offered by employers with at least 100 employees.2
But the rule’s requirements do not extend to every employer health plan. Fully insured plans are excluded, as are plans whose sponsors are certain drug supply chain entities or their affiliates, including manufacturers, distributors, wholesalers, PBMs, and rebate aggregators.1,2 Employers should confirm coverage rather than assume that plan size alone determines applicability.
The rule takes effect January 4, 2027, and applies to plan years beginning on or after July 1, 2027.1,2 For calendar-year plans, the requirements generally apply beginning January 1, 2028.1,2 These dates do not suspend existing ERISA fiduciary duties or applicable statutory disclosure obligations.2-4
PBM Compensation Extends Beyond the Administrative Fee
The required disclosures address direct compensation paid by the plan or plan sponsor and indirect compensation received from other sources.1,2 They include manufacturer rebates and other payments, spread compensation, pharmacy recoupments, and amounts received under price protection arrangements.1,2 The rule also addresses certain formulary incentives and arrangements that direct patients to PBM-affiliated pharmacies.1,2
For employers, the review should begin with the definitions in the PBM agreement. A representation to pass through 100% of “rebates” may leave other manufacturer payments outside the contractual definition if rebates are not specifically defined. Payments retained by a rebate aggregator or another affiliate may also affect the economics of the arrangement. Employers should compare the required disclosures against the agreement to determine what is being retained, what must be passed through, and whether the reported amounts are consistent with the contract.
Disclosure of a payment does not, by itself, establish that the employer is entitled to receive it. An employer may need to negotiate broader pass-through provisions or pursue an existing contractual right. That distinction matters when moving from identifying PBM revenue to determining whether money is owed to the plan.
Disclosures Must Arrive Before Contract Decisions Are Made
Covered service providers must provide initial disclosures reasonably in advance of entering into, extending, or renewing an arrangement.1,2 For renewals and extensions, providing disclosures at least 90 calendar days in advance is considered reasonable.1,2 Employers should negotiate earlier delivery when necessary to accommodate their own review and contracting process.
Contractual notice deadlines deserve particular attention. If an employer must give notice of nonrenewal 180 days before expiration, a disclosure delivered 90 days before renewal may arrive after the employer’s opportunity to exit has passed. Disclosure deadlines should therefore be coordinated with termination, nonrenewal, and procurement deadlines.
The rule also requires ongoing disclosures every 6 months, or quarterly at the plan’s request, generally within 30 calendar days after the reporting period.1,2 A compensation category that exceeds its corresponding initial estimate by at least 5% generally requires an explanation, with lower thresholds permitted by written agreement.1,2 Amounts passed through to the plan are excluded from that overage calculation.1 Employers should examine the explanation and determine whether the increase reflects utilization changes, additional compensation, or another development requiring follow-up.
Audit Rights Allow Employers to Verify the Disclosures
Covered plans may audit the required disclosures at least annually and independently select their auditor.1,2 Covered service providers generally must acknowledge an audit request within 10 business days and provide the necessary information within 60 calendar days, subject to applicable exceptions.1,2 Relevant information may include claims and transaction-level data and contracts with pharmacies, manufacturers, and rebate aggregators, subject to reasonable confidentiality protections.1
These rights can help employers determine whether the reported compensation matches the underlying transactions. A summary report showing an aggregate rebate amount, for example, may be insufficient to evaluate whether all contractually required payments were credited to the plan. The supporting records can establish how the amount was calculated and identify discrepancies requiring further review.
The regulatory audit right focuses on verifying the required disclosures.1 Employers should also preserve broader contractual rights to examine pricing guarantees, rebate payments, and other performance obligations. The agreement should address access to records and remedies for underpayments or overcharges, including rights that remain available after termination.
What the Rule Could Mean for Independent Pharmacies
Independent pharmacies could benefit if and when employers use these disclosures to scrutinize PBM practices affecting reimbursement and patient choice. Greater visibility into spread compensation may help demonstrate that reducing pharmacy reimbursement does not necessarily reduce the employer’s cost.1,5 When the plan’s payment remains unchanged, a lower payment to the pharmacy can increase the amount retained by the PBM.5
Pharmacy recoupment disclosures may also prompt employers to examine whether recoveries benefit their plans.1,2 When a PBM recoups money through an audit or another retroactive adjustment, the employer should determine how that recovery is treated under its agreement and whether any required credit was received. A reported recovery from a pharmacy should be reconciled with the plan’s financial records before it is accepted as a plan saving.
Disclosures concerning affiliated-pharmacy steering could support closer review of network restrictions.1,2 Employers may be better positioned to evaluate whether requiring patients to use a PBM-affiliated specialty or mail-order pharmacy produces demonstrable savings and adequate access.5 Independent pharmacies can support that evaluation with evidence of their pricing, clinical services, and ability to maintain continuity of care.
These are potential benefits, not guaranteed outcomes. The disclosure rule itself does not establish minimum pharmacy reimbursement, prohibit spread pricing or affiliated-pharmacy steering, or give independent pharmacies the disclosure and audit rights afforded to covered plans.1 An employer’s reduction in PBM costs also does not ensure that pharmacies will receive higher reimbursement. Any benefit will depend on the changes employers pursue and the terms they obtain.
Plan Fiduciaries Need a Process for Acting on the Information
The rule operates within ERISA’s prohibited transaction exemption for service arrangements and supports fiduciaries’ existing responsibility to assess whether services and compensation are reasonable.1,3,4 Receiving the required disclosures does not complete that assessment. Fiduciaries should document who reviewed the information, what concerns were identified, and how those concerns were resolved.
When a PBM fails to provide required information, fiduciaries should evaluate the conditions for available statutory and regulatory relief, including applicable request and DOL notification requirements.1,2 The protections are conditional. Continuing the arrangement without addressing missing information can create a separate problem for the plan fiduciary.3,4
Employers should review their PBM agreements now, align disclosure deadlines with contracting decisions, and assign responsibility for ongoing review. Where the information identifies unexplained compensation or a possible contractual shortfall, the next step should be a focused request for supporting records and an assessment of available remedies.
For independent pharmacies, the opportunity is to help employers understand where reimbursement practices and network restrictions affect both plan spending and patient care.
READ MORE:
REFERENCES
1. Improving transparency into pharmacy benefit manager fee disclosure: final rule. Fed Regist. 2026;91:69092-69196. To be codified at 29 CFR §2550. Accessed November 16, 2026. https://www.federalregister.gov/d/2026-22306
2. Pharmacy benefit manager fee disclosure final rule. Fact sheet. October 2026. Accessed November 16, 2026. https://www.dol.gov/agencies/ebsa/about-ebsa/our-activities/resource-center/fact-sheets/pharmacy-benefit-manager-fee-disclosure-final-rule
3. Employee Retirement Income Security Act of 1974 §404(a)(1)(A)-(B), 29 USC §1104(a)(1)(A)-(B). Accessed November 16, 2026. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title29-section1104&num=0&edition=prelim
4. Employee Retirement Income Security Act of 1974 §408(b)(2), 29 USC §1108(b)(2). Accessed November 16, 2026. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title29-section1108&num=0&edition=prelim
5. Federal Trade Commission Office of Policy Planning. Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers. Second interim staff report. January 2025. Accessed November 16, 2026. https://www.ftc.gov/reports/specialty-generic-drugs-growing-profit-center-vertically-integrated-pharmacy-benefit-managers
Related to this article








